Your FDA Clearance Is Not a Predicate in India
Your FDA Clearance Is Not a Predicate in India- What Global Manufacturers Get Wrong
By Ankur Khare — Biomedical Engineer | Regulatory Affairs Specialist | Founder, MedReg Intel
Most medical device companies entering India make the same assumption.
"We have FDA clearance. We have a predicate. India will be straightforward."
It is not straightforward. And the misunderstanding costs months — sometimes years.
The Assumption That Breaks Applications
When a manufacturer has US FDA 510(k) clearance, they have demonstrated substantial equivalence to a predicate device — a device previously cleared by FDA in the United States.
That US predicate has no standing in India.
India's regulatory framework under MDR 2017 defines predicate device independently, in Rule 3(zm):
"A device, first time and first of its kind, approved for manufacture for sale or for import by the Central Licensing Authority and has the similar Intended Use, Material of Construction and Design Characteristics as the device which is proposed for license in India."
Read that carefully.
The predicate must have been approved by India's Central Licensing Authority. Not FDA. Not a CE Notified Body. Not any other global regulator. A device cleared in the United States, Europe, or Japan does not become an Indian predicate by virtue of that clearance.
This is not a technicality. It is the foundation of how your entire application pathway is determined.
Two Pathways — Completely Different Outcomes
Whether or not an Indian predicate exists determines which application form you file, what documentation you need, what timelines you face, and whether clinical data will be required. These are not minor differences.
When an Indian predicate exists:
Your device has similar intended use, materials, and design to a device already licensed by CDSCO. You file MD-14 for import or MD-7 and MD-9 for manufacture. This is an established pathway with a predictable review process. A clean, complete application for a Class C device typically resolves in six to eighteen months.
When no Indian predicate exists:
No device of this type has ever been licensed by CDSCO before. Under MDR 2017, your device is classified as a New Device. You file MD-26 for import or for manufacture. This pathway involves a more complex assessment — CDSCO is evaluating a device category it has not previously regulated. Documentation requirements are higher. Scrutiny is greater. Timelines are longer — typically twelve to twenty-four months for a clean application, and often considerably more.
The difference between these two pathways is not just administrative. It affects product launch timelines, cash flow, competitive positioning, and the resources you need to allocate to the regulatory process.
The Three-Criteria Test — Where Partial Matches Create Problems
Even when manufacturers correctly identify a potential Indian predicate, applications run into difficulty because the match is partial rather than complete.
MDR 2017 Rule 3(zm) requires similarity on three distinct criteria — intended use, material of construction, and design characteristics. All three must align. A device that matches on two of three will attract a classification query during review, which adds months to the timeline and may ultimately result in the application being rerouted to the New Device pathway anyway.
Intended use must be clinically precise. A predicate approved for use in adults is not automatically a valid predicate for a paediatric version of the same device. A predicate approved for single use is not automatically a valid predicate for a reusable version. These distinctions matter and will be examined during review.
Material of construction is equally specific. A catheter made from polyurethane and a catheter made from silicone serve similar clinical purposes but are not materially equivalent. Write your predicate justification accordingly.
Design characteristics require honest analysis. If your device has additional features, modified geometry, or a different mechanism of action from the potential Indian predicate, document why those differences do not affect the equivalence claim — or acknowledge that the differences place your device in the New Device pathway.
A one-page written predicate justification that addresses all three criteria systematically will save time at review. Most applications do not include one.
The IVD Distinction That Adds Confusion
For In Vitro Diagnostics, the pathway for a device without an Indian predicate is designated as a New IVD — not an Investigational Device. This distinction matters. The regulatory route, documentation requirements, and assessment process differ from the pathway for medical devices without predicates. Treating IVDs and medical devices as equivalent in this context is a separate and common error that compounds the predicate confusion.
If your product is an IVD — a reagent, a test kit, an analyser — verify the specific pathway before selecting your form. The IVD framework under MDR 2017 has its own logic.
What FDA Clearance Actually Gives You in India
FDA 510(k) clearance is not without value in an Indian application. It demonstrates that the device has undergone regulatory scrutiny in a recognised market. It provides supporting evidence for safety and performance claims. For Class C and D devices, it can form part of the clinical evidence package.
What it does not do is determine your Indian regulatory pathway, substitute for an Indian predicate, or reduce the documentation requirements of your application.
CE certification under EU MDR 2017/745 carries similar weight — useful evidence, not regulatory currency. India's framework requires Indian compliance demonstrated through India's process.
This is not an arbitrary position. It reflects regulatory sovereignty — the principle that each jurisdiction determines its own standards for market access. Understanding this early saves significant time and resource later.
Three Questions Before You File
Before selecting any application form on SUGAM, answer these three questions clearly:
One — Has any device of this category ever been licensed by CDSCO? Check the MD Online database on cdsco.gov.in. Do not assume that because a device has been available globally for years it has an Indian predicate. Many widely used device categories have never been formally licensed in India.
Two — Does your potential predicate genuinely match on all three criteria? Intended use, material of construction, and design characteristics — all three, not two of three. Write out the comparison before you file.
Three — Is your product a medical device or an IVD? The predicate concept applies to both, but through different pathways. Confirm your classification and the applicable form before proceeding.
The Honest Picture
India's medical device regulatory framework is not a simplified or derivative version of FDA or CE. It is an independent system with its own predicate logic, its own classification criteria, its own evidentiary requirements, and its own review process.
FDA clearance is useful background. CE marking is recognised evidence. Neither is a substitute for understanding what Indian regulation actually requires.
The manufacturers who move efficiently through CDSCO's process are not the ones who assume alignment with global frameworks. They are the ones who verify India-specific requirements before they file — not after their first deficiency notice arrives.
Regulatory approval in India is not won by assuming. It is won by understanding exactly where India's framework differs from the one you already know — and preparing accordingly.
If you are determining the correct pathway for a device in India and want a second opinion before filing, reach out: ankur@medregintel.com
MedReg Intel publishes practical regulatory intelligence for Indian medical device manufacturers, importers, and startups. Visit medregintel.com
This article is for educational purposes and does not constitute formal regulatory or legal advice.
Comments
Post a Comment